Titan Medical Announces Publication of Patent Application Expanding Commitment to Continued Innovation in Single Access Robot-Assisted Surgery
Strengthens the company’s intellectual property portfolio with innovations in next-generation single-port RAS technology
TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) — Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on developing and commercializing innovative surgical technologies for access robot-assisted surgery (RAS), today announced the publication of International Patent Application No. PCT/CA2022/050392, which the company plans to pursue in the United States and other key markets under the Cooperation Treaty. in patent matters (PCT).
The patent application generally describes endoscope technologies suitable for use with RAS systems that are designed to provide a robust workspace field of view superior to those provided by prior endoscope technologies, which are designed to capture only part of a surgical site. The technology described in the patent application could be used in a variety of single-port RAS systems, including those designed to support three instruments that can be simultaneously positioned in an insertion conduit.
“It was important for us to share the publication of this patent application as it underscores our continued commitment to be an innovation leader in the area of Single Access RAS, which includes but also extends beyond development. of the Enos™ Surgical System,” said Cary Vance. , President and CEO of Titan. “While we are focused on the development, clinical and regulatory activities of the Enos System, we are committed to continuing to advance the surgical experience for patients, surgeons and hospitals through research and development of components and RAS technology systems. Filing patent applications on our inventions remains an important step in protecting the value we continue to generate, including those designed for next-generation technologies and systems. As we innovate and grow our RAS technology roadmap, we plan to expand our leadership in one-stop innovation and intellectual property, positioning Titan competitively, especially against future entrants. RAS.
Titan has developed an extensive intellectual property portfolio with over 220 patents pending and granted spanning the United States and other jurisdictions that support and cover various aspects of Single Access RAS, including the surgeon’s workstation of the Enos system, patient cart, dexterous articulating instruments, ergonomic hand controllers, enhanced vision systems, advanced control software and instinctive surgeon overlays to provide interoperative feedback. This coverage of Single Access RAS, and in particular the Enos system, as well as coverage of more general aspects of RAS technologies, can provide the company with multiple intellectual property options, including increased protection of its RAS technologies. and the ability to further license its technologies. and assistance in securing a competitive trade route.
About Titan Medical
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company headquartered in Toronto, Ontario, and operating in Chapel Hill, North Carolina, is focused on improving the robot-assisted surgery (RAS) using innovative technology through a single point of access. The Enos™ Single Access Robotic Surgical System is being developed with an ergonomic focus to provide a surgical experience that mimics the real movements required by surgeons and includes multi-articulated instruments designed to allow surgeons a greater range of motion in a confined space, with the dexterity and ability to exert the forces necessary to perform routine surgical tasks. With the Enos system, Titan initially intends to pursue gynecological surgical indications.
Enos™ is a trademark of Titan Medical Inc.
For more information, visit www.titanmedicalinc.com and follow @TitanMedical on Twitter and LinkedIn.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of applicable Canadian and United States securities laws, which reflect management’s current expectations regarding future growth, results of operations, performance and prospects and opportunities. business of the company. Forward-looking statements are frequently, but not always, identified by words such as “may”, “could”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”. , “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, but are not limited to, references to the following: the company’s plans under the PCT; the potential benefits of the company’s technologies, including adroit endoscope technologies providing a robust field of view of the workspace; the technology described in the patent application being used in a variety of single port RAS systems; the company’s commitment to be an innovation leader in single access RAS, which includes but also extends beyond the Enos system; the company’s commitment to advancing the surgical experience for patients, surgeons and hospitals; the company’s expectation to expand its leadership in single-entry innovations and intellectual property; the company’s competitive position, including against future RAS entrants; the coverage and options offered by the company’s intellectual property portfolio; the Enos Single Access Robotic Surgical System being developed with an ergonomic focus to provide a surgical experience that mimics the real movements required by surgeons; and that Titan intends to pursue gynecological surgical indications initially. These statements reflect management’s current beliefs regarding future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Report for the year ended December 31, 2021, which may be viewed at www.sedar.com and at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may differ materially from those expressed or implied by the forward-looking statements contained in this press release. These factors should be carefully considered and potential investors should not place undue reliance on forward-looking statements. Although the forward-looking statements contained in the press release are based on what management currently believes to be reasonable assumptions, the company cannot assure potential investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the company expressly disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact
Kristen Galfetti
Vice President, Investor Relations
& Business communication
+1-781-869-2553
investors@titanmedicalinc.com
###
